Display options
Cite
Ocadlikova D, Lecciso M, Isidori A, et al. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019;9:1004doi: 10.3389/fonc.2019.01004.
Ocadlikova, D., Lecciso, M., Isidori, A., Loscocco, F., Visani, G., Amadori, S., Cavo, M., & Curti, A. (2019). Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Frontiers in oncology, 91004. https://doi.org/10.3389/fonc.2019.01004
Ocadlikova, Darina, et al. "Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia." Frontiers in oncology vol. 9 (2019): 1004. doi: https://doi.org/10.3389/fonc.2019.01004
Ocadlikova D, Lecciso M, Isidori A, Loscocco F, Visani G, Amadori S, Cavo M, Curti A. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019 Oct 09;9:1004. doi: 10.3389/fonc.2019.01004. eCollection 2019. PMID: 31649875; PMCID: PMC6794495.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2019 Oct 09;9:1004. doi: 10.3389/fonc.2019.01004. eCollection 2019.

Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia.

Frontiers in oncology

Darina Ocadlikova, Mariangela Lecciso, Alessandro Isidori, Federica Loscocco, Giuseppe Visani, Sergio Amadori, Michele Cavo, Antonio Curti

Affiliations

  1. Department of Hematology and Oncology, University Hospital S.Orsola-Malpighi, Institute of Hematology "L. and A. Seràgnoli", Bologna, Italy.
  2. Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
  3. Department of Medicine, Institute of Hematology, University Hospital Tor Vergata, Rome, Italy.

PMID: 31649875 PMCID: PMC6794495 DOI: 10.3389/fonc.2019.01004

Abstract

In solid tumors and hematological malignancies, including acute myeloid leukemia, some chemotherapeutic agents, such as anthracyclines, have proven to activate an immune response via dendritic cell-based cross-priming of anti-tumor T lymphocytes. This process, known as immunogenic cell death, is characterized by a variety of tumor cell modifications, i.e., cell surface translocation of calreticulin, extracellular release of adenosine triphosphate and pro-inflammatory factors, such as high mobility group box 1 proteins. However, in addition to with immunogenic cell death, chemotherapy is known to induce inflammatory modifications within the tumor microenvironment, which may also elicit immunosuppressive pathways. In particular, DCs may be driven to acquire tolerogenic features, such as the overexpression of indoleamine 2,3-dioxygensase 1, which may ultimately hamper anti-tumor T-cells via the induction of T regulatory cells. The aim of this review is to summarize the current knowledge about the mechanisms and effects by which chemotherapy results in both activation and suppression of anti-tumor immune response. Indeed, a better understanding of the whole process underlying chemotherapy-induced alterations of the immunological tumor microenvironment has important clinical implications to fully exploit the immunogenic potential of anti-leukemia agents and tune their application.

Copyright © 2019 Ocadlikova, Lecciso, Isidori, Loscocco, Visani, Amadori, Cavo and Curti.

Keywords: T regulatory cells; acute myeloid leukemia; dendritic cells; immunogenic cell death; immunosuppression

References

  1. Int J Hematol. 2013 Nov;98(5):558-62 - PubMed
  2. Int J Mol Sci. 2018 Feb 16;19(2):null - PubMed
  3. Nat Med. 2014 Nov;20(11):1301-9 - PubMed
  4. Leukemia. 2012 Oct;26(10):2186-96 - PubMed
  5. Front Immunol. 2018 Jun 05;9:1274 - PubMed
  6. Nat Med. 2007 Jan;13(1):54-61 - PubMed
  7. Tumour Biol. 2013 Feb;34(1):531-42 - PubMed
  8. J Immunol. 2018 Jan 15;200(2):375-383 - PubMed
  9. Clin Immunol. 2018 Mar;188:67-73 - PubMed
  10. Blood. 2007 Apr 1;109(7):2871-7 - PubMed
  11. Blood. 2011 Apr 28;117(17):4501-10 - PubMed
  12. Nat Rev Cancer. 2012 Mar 22;12(4):237-51 - PubMed
  13. Oncoimmunology. 2017 Jan 10;6(4):e1278332 - PubMed
  14. Immunol Rev. 2011 May;241(1):77-88 - PubMed
  15. Int J Biochem Cell Biol. 2012 Jun;44(6):842-6 - PubMed
  16. Cell Death Differ. 2014 Jan;21(1):69-78 - PubMed
  17. Genes Dis. 2018 May 17;5(3):194-203 - PubMed
  18. Autophagy. 2013 Sep;9(9):1292-307 - PubMed
  19. Science. 2011 Dec 16;334(6062):1573-7 - PubMed
  20. Cell Death Differ. 2014 Jan;21(1):79-91 - PubMed
  21. Int J Clin Exp Pathol. 2014 Sep 15;7(10):6880-8 - PubMed
  22. Oncoimmunology. 2013 Jun 1;2(6):e24568 - PubMed
  23. Oncoimmunology. 2014 Dec 13;3(9):e955691 - PubMed
  24. Cell Death Differ. 2014 Jan;21(1):39-49 - PubMed
  25. Genes Dev. 2018 Oct 1;32(19-20):1267-1284 - PubMed
  26. Curr Opin Hematol. 2018 Mar;25(2):136-145 - PubMed
  27. Oncoimmunology. 2014 Apr 16;3:e28473 - PubMed
  28. Br J Haematol. 2018 Apr;181(1):38-53 - PubMed
  29. Blood. 2007 Jun 1;109(11):4839-45 - PubMed
  30. Oncotarget. 2015 Dec 8;6(39):41600-19 - PubMed
  31. Blood. 2010 Oct 7;116(14):2484-93 - PubMed
  32. Blood Cancer J. 2015 Jul 31;5:e330 - PubMed
  33. J Clin Oncol. 2011 Feb 10;29(5):487-94 - PubMed
  34. Nat Med. 2009 Oct;15(10):1170-8 - PubMed
  35. Sci Rep. 2017 Nov 2;7(1):14915 - PubMed
  36. Expert Rev Anticancer Ther. 2019 May;19(5):393-404 - PubMed
  37. Immunity. 2013 Jul 25;39(1):74-88 - PubMed
  38. Immunol Lett. 2018 Jan;193:25-34 - PubMed
  39. PLoS One. 2011;6(11):e28217 - PubMed
  40. Curr Opin Immunol. 2008 Oct;20(5):545-57 - PubMed
  41. PLoS One. 2009 Sep 10;4(9):e6982 - PubMed
  42. Cancer Metastasis Rev. 2011 Mar;30(1):61-9 - PubMed
  43. Blood. 2016 Dec 29;128(26):3113-3124 - PubMed
  44. Cell Death Dis. 2010 Dec 02;1:e104 - PubMed
  45. Oncotarget. 2014 Dec 30;5(24):12472-508 - PubMed
  46. Annu Rev Immunol. 2013;31:51-72 - PubMed
  47. Biomed Pharmacother. 2018 Jan;97:225-232 - PubMed
  48. Photochem Photobiol Sci. 2011 May;10(5):670-80 - PubMed
  49. J Hepatol. 2013 Sep;59(3):583-94 - PubMed
  50. Cancer Res. 2010 Nov 15;70(22):9062-72 - PubMed
  51. Leuk Lymphoma. 2018 Apr;59(4):790-802 - PubMed
  52. Cell Biochem Biophys. 2014 Sep;70(1):273-7 - PubMed
  53. Purinergic Signal. 2012 Sep;8(3):343-57 - PubMed
  54. Blood. 2011 Jan 13;117(2):608-17 - PubMed
  55. Leukemia. 2007 Feb;21(2):353-5 - PubMed
  56. Oncogene. 2010 Jan 28;29(4):482-91 - PubMed
  57. Cancer Res. 2013 Jan 15;73(2):605-16 - PubMed
  58. Nat Rev Cancer. 2012 Dec;12(12):860-75 - PubMed
  59. Cell Death Dis. 2013 May 16;4:e631 - PubMed
  60. Immunity. 2013 Apr 18;38(4):729-41 - PubMed
  61. PLoS One. 2011 Apr 18;6(4):e18925 - PubMed
  62. Nat Commun. 2018 Nov 7;9(1):4644 - PubMed
  63. Cancer Immunol Immunother. 2013 Feb;62(2):203-16 - PubMed
  64. Autophagy. 2012 Mar;8(3):413-5 - PubMed
  65. Expert Rev Hematol. 2014 Dec;7(6):807-18 - PubMed
  66. World J Gastroenterol. 2010 May 21;16(19):2428-34 - PubMed
  67. Nat Med. 2007 Sep;13(9):1050-9 - PubMed
  68. Cancer Res. 2011 Feb 1;71(3):768-78 - PubMed
  69. Haematologica. 2010 Dec;95(12):2022-30 - PubMed
  70. Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33 - PubMed
  71. J Clin Invest. 2010 Apr;120(4):1111-24 - PubMed
  72. Photochem Photobiol Sci. 2014 Mar;13(3):474-87 - PubMed
  73. Cancer Res. 2011 Jul 15;71(14):4821-33 - PubMed
  74. Cancer Res. 2010 Feb 1;70(3):855-8 - PubMed
  75. EMBO J. 2009 Mar 4;28(5):578-90 - PubMed
  76. J Exp Med. 2005 Dec 19;202(12):1691-701 - PubMed
  77. Cancer Res. 2013 Jun 15;73(12):3499-510 - PubMed
  78. Blood. 2017 Jan 26;129(4):424-447 - PubMed
  79. Cytokine. 2017 Sep;97:123-132 - PubMed
  80. Br J Cancer. 2010 Jan 5;102(1):115-23 - PubMed
  81. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  82. Cancer Res. 2016 Apr 1;76(7):1746-56 - PubMed
  83. Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):E5608-17 - PubMed
  84. Front Immunol. 2017 Jun 07;8:496 - PubMed
  85. Front Immunol. 2018 Feb 27;9:385 - PubMed
  86. Cell Death Differ. 2014 Jan;21(1):26-38 - PubMed
  87. Nat Rev Mol Cell Biol. 2012 Dec;13(12):780-8 - PubMed
  88. Biofactors. 2013 Jul-Aug;39(4):355-67 - PubMed
  89. Oncoimmunology. 2012 Oct 1;1(7):1218-1219 - PubMed
  90. PLoS One. 2013 Jun 07;8(6):e65181 - PubMed
  91. Sci Transl Med. 2012 Jul 18;4(143):143ra99 - PubMed
  92. Front Immunol. 2017 Dec 22;8:1918 - PubMed
  93. Oncol Rep. 2011 Jun;25(6):1549-56 - PubMed
  94. Hum Pathol. 2013 Dec;44(12):2677-83 - PubMed
  95. Sci Transl Med. 2010 Dec 22;2(63):63ra94 - PubMed
  96. Biochim Biophys Acta. 2010 Jan;1805(1):53-71 - PubMed
  97. Leukemia. 2011 May;25(5):792-9 - PubMed
  98. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801 - PubMed
  99. Int J Cancer. 2014 Sep 1;135(5):1165-77 - PubMed
  100. Expert Rev Hematol. 2018 May;11(5):373-389 - PubMed
  101. Science. 2017 Jul 28;357(6349): - PubMed
  102. Leukemia. 2012 Sep;26(9):2148-51 - PubMed
  103. Adv Exp Med Biol. 2017;1036:91-104 - PubMed
  104. Curr Opin Immunol. 2012 Apr;24(2):233-8 - PubMed
  105. Cell Death Differ. 2007 Jul;14(7):1237-43 - PubMed
  106. Cancer Immunol Immunother. 2010 Dec;59(12):1839-49 - PubMed
  107. Am J Hematol. 2016 Aug;91(8):824-46 - PubMed
  108. EBioMedicine. 2017 Aug;22:44-57 - PubMed
  109. Clin Cancer Res. 2013 Mar 1;19(5):1225-31 - PubMed
  110. Oncoimmunology. 2012 Mar 1;1(2):179-188 - PubMed

Publication Types